Omega Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Omega Therapeutics's estimated annual revenue is currently $16.3M per year.
- Omega Therapeutics's estimated revenue per employee is $117,935
- Omega Therapeutics's total funding is $239.4M.
- Omega Therapeutics's current valuation is $509.3M. (January 2022)
Employee Data
- Omega Therapeutics has 138 Employees.
- Omega Therapeutics grew their employee count by 6% last year.
Omega Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Chief Scientific Officer | Reveal Email/Phone |
3 | Chief Staff | Reveal Email/Phone |
4 | SVP, Finance | Reveal Email/Phone |
5 | SVP, Head Regulatory Affairs | Reveal Email/Phone |
6 | VP, Intellectual Property (IP) | Reveal Email/Phone |
7 | VP, Data and IT | Reveal Email/Phone |
8 | Executive Director, Finance | Reveal Email/Phone |
9 | Senior Director, Cancer Biology | Reveal Email/Phone |
10 | Executive Director, Program and Alliance Management | Reveal Email/Phone |
Omega Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Omega Therapeutics?
Omega Therapeuticsￃﾢ￢ﾀﾞￂﾢ is a preclinical stage genomic medicine enterprise transforming medicine and patient care through precision genomic control. The companyￃﾢ￢ﾂﾬ￢ﾄﾢs platform is focused on selectively directing the human genome to treat and cure disease by precisely controlling genomic expression without changing nucleic acid sequences. We are developing precision therapeutics for a range of disease indications including rare genetic diseases, immunology, inflammation, metabolic diseases and oncology. # transformativemedicines #pioneeringmedicines
keywords:N/A
$239.4M
Total Funding
138
Number of Employees
$16.3M
Revenue (est)
6%
Employee Growth %
$509.3M
Valuation
N/A
Accelerator
Omega Therapeutics News
Get Omega Therapeutics alerts: Hedge funds and other institutional investors have recently added to or reduced their stakes in the business.
Omega Therapeutics Presents Preclinical Data on OTX-2002, First-in-Class Epigenomic Controller, as Potential Treatment for Hepatocellular...
(Nasdaq: OMGA) ("Omega"), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new...
CAMBRIDGE, Mass., Sept. 10, 2021 /PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programing™ pl ...
CAMBRIDGE, Mass, July 29, 2021 /PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a development-stage biotechnology company leveraging its OMEGA Epigenomic Programming™ platform to harness the power of epigenetics to develop a new class of DNA-sequence-targeting, mRNA-encoded p ...
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $35.1M | 138 | 10% | N/A |
#2 | $37.5M | 139 | 1% | N/A |
#3 | $34.1M | 139 | 24% | N/A |
#4 | $28.4M | 139 | 51% | N/A |
#5 | N/A | 139 | 72% | N/A |